Stockholm-based BOOST Pharma, a clinical-stage biopharmaceutical firm centered on creating novel cell therapies for uncommon skeletal pediatric illnesses, right this moment introduced that Sound Bioventures has joined its investor syndicate with a €3.1 million funding.
The financing will help continued medical growth of BT-101, BOOST Pharma’s pioneering stem cell-based remedy for osteogenesis imperfecta (OI), often known as brittle bone illness.
“We’re honored to welcome Sound Bioventures to our syndicate – a collaborative, hands-on investor group that shares our imaginative and prescient of remodeling care for youngsters dwelling with uncommon skeletal illnesses,” mentioned Ingelise Saunders, Chair of BOOST Pharma. “Their dedication strengthens BOOST Pharma’s place as a pacesetter in cell remedy for genetic bone issues and permits continued progress of BT-101 in direction of the clinic.”
This funding into BOOST Pharma displays a wider sample of European funding for superior cell- and gene-therapy ventures in 2025.
In Sweden, Cellcolabs raised €10.3 million to scale manufacturing of mesenchymal stem cells, aiming to cut back manufacturing prices and increase entry to regenerative remedies. In Germany, Akribion Therapeutics secured €8 million for its programmable cell-depletion platform, whereas Finland’s StemSight attracted €2.3 million to progress stem-cell therapies for restoring imaginative and prescient. In neighbouring Denmark, Fuse Vectors closed €4.9 million to develop its cell-free viral vector know-how supporting gene-therapy supply.
With each BOOST Pharma and Cellcolabs headquartered in Sweden, the nation reveals a rising focus of regenerative-medicine innovation, reinforcing Sweden’s and Europe’s broader dedication to clinical-stage biotech growth.
“We consider BOOST Pharma’s modern method to treating osteogenesis imperfecta has huge potential to ship not solely medical influence for sufferers but in addition sturdy worth creation. We look ahead to working collectively to succeed in new milestones,” mentioned Johan Kördel, Managing Accomplice at Sound Bioventures.
Based in 2019, BOOST Pharma is predicated on years of collaborative analysis from Karolinska Institute in Stockholm with the concentrate on novel cell remedy remedies for Osteogenesis Imperfecta. The analysis groups of affiliate professor Cecilia Götherström and professor Magnus Westgren have reportedly proven that that remedy with BOOST Cells tremendously enhanced the standard of life for sufferers affected by this in any other case extraordinarily debilitating illness.
BOOST Pharma has made vital progress advancing BT-101, a novel mesenchymal stem cell remedy meant for youngsters born with OI. BT-101 is designed for early intervention, administered to infants to deal with the underlying reason behind OI and scale back fracture frequency in affected kids.
In mice fashions, BT-101 has proven that cell remedy results in greater calcium deposition, greater alkaline phosphatase exercise, and a excessive ectopic bone formation.
As soon as injected, cells will migrate to the bone of sufferers with OI, the place they are going to engraft and begin bone formation. BOOST Pharma obtained human proof-of-concept for BT-101 after 4 kids with Sort III and IV OI have been handled; the kids have been adopted for years as much as adolescence.
BT-101 allegedly reveals nice promise for the effectiveness of treating kids with OI: the kids handled adopted their very own development curve, had elevated lengthwise development in comparison with modern OI sufferers and confirmed a big discount of bone fractures. The cells are thought of to be protected with no opposed reactions and no immune responses in direction of the donor MSC.
BT-101 remedy begins on the prenatal stage, when OI is first identified, or as early as doable after the kid is born. By treating this early, BOOST Pharma is addressing the illness on the earliest doable stage, thereby growing the remedy advantages for the affected person in later years, akin to robust bones and presumably improved lung operate.
With this new funding, BOOST Pharma goals to speed up medical growth and transfer nearer to delivering the primary disease-modifying remedy for OI.